Overview
Maravai is committed to environmentally and socially responsible growth. We recognize that acting with a sustainability mindset is critical to serving our stakeholders, including our team members, investors, customers, supplier partners, and the communities where we live and work. Our commitment to ESG is enterprise-wide and connects every individual across our organization.
Our ESG practices are fundamental to realizing our vision of a world where scientists are limited only by the boundaries of their imaginations – and where we can expand those boundaries for every vaccine, therapeutic and diagnostic company on the planet.
Our 2023 ESG report
Beginning with our inaugural report for 2021, we committed to sharing our ESG performance annually. This report outlines our core initiatives and performance metrics for the 2023 fiscal year.
Contact: esg@maravai.com
View our ESG reportOur ESG Framework
ESG oversight
Primary oversight of our ESG strategy and related risks is managed by the Nominating, Governance, and Risk (NGR) Committee of our Board of Directors (the Board). Responsibilities for ESG factors across our organization are defined at Board, Nominating, Governance, and Risk Committee, and management levels. Implementing those responsibilities is shared across departments and portfolio businesses.
Our ESG priorities
Our ESG framework informs our strategy and guides our approach to managing ESG risks and opportunities to achieve sustainable growth. Our framework focuses on the following key topics: Product innovation, Our people, Governance leadership, and Sustainable growth.
In 2023, we conducted Maravai’s first stakeholder assessment to identify and prioritize the ESG issues that are most important to our company and stakeholders.
Product innovation
We can contribute to the future of human health and the development of lifechanging medicine through the products we develop. Fundamental to our innovation is product quality and safety. By implementing robust processes for our organization and oversight of our supply chain, we will confidently expand the production of our vital ingredients for leading scientists worldwide. By expanding our reach and developing new technologies, we support more customers to achieve their ambitions of transforming human health.
- 3,000+ - Our portfolio includes over 3,000 products designed to support life-changing medicines and diagnostics
- 100+ – CleanCap®, technology used in more than 100 new pre-clinical and clinical programs launched in 2023, growing from 250 programs to more than 350 programs
- 7 - New catalog products introduced by Glen Research in 2023
- 420 – Diverse suppliers are in the Maravai network
- 100% - All our manufacturing sites in operation in 2023 are certified to the internationally recognized quality management standard ISO 9001:2015 and audited annually for compliance.
Our people
Operating a sustainable business begins with our people
We can empower our employees to contribute to our mission by increasing engagement, supporting their health and wellbeing, and embedding diversity, equity, and inclusion (DEI) best practices into our recruitment, rewards, talent, and training programs. Understanding and fostering the social values of our people is an important part of our community engagement strategy.
- 97% - Our employee engagement survey participation rate was 97%. The survey received 2,700 comments
- 100% - All our employees completed annual workplace diversity, inclusion, and sensitivity training in 2023
- 830 - Our employees completed 830 voluntary, non-compliance training courses.
- 640 - More than 80 employees volunteered their time using an Impact Day and donated more than 640 hours of community service
- $19K+ - Employee contributions of over $19K to non-profit organization were matched by Maravai
- $300,000 – The Maravai LifeSciences Foundation donated $300,000 and supported 10 organizations that make a difference in the communities where we live and work
Governance leadership
Business resilience
We can build resilience through sustainable leadership, strategic risk management, and effective governance. By developing cross functional partnerships, we will drive the collaboration and accountability we need to consistently achieve our ESG objectives.
A focused and robust corporate governance program underpins our long-term success. It ensures our Board has clear visibility of major risks to our company, including issues related to sustainability and ESG, as set out in our Corporate Governance Guidelines.
- In 2023, 100% - The standing Committees of our Board were chaired by women who are independent board members
- We announced a new program to elect a dedicated ethics liaison at different levels of Maravai
- Formally adopted the ‘Rooney Rule’ for director nominees
- All employees review and acknowledge our Code of Business Conduct and Ethics Policy annually and receive training during onboarding and annually thereafter.
Sustainable growth
We can improve the sustainability of our operations by promoting innovation and collaboration to reduce our environmental impact. As part of our commitment to improve human health, we take pride in our efforts to protect the health of the planet for future generations. Our approach to environmental stewardship involves a combination of sustainability strategies, such as reducing our emissions, waste, water, and energy use while continuously improving our data management processes and reporting practices.
- We increased the scope of our GHG emissions reporting to include Scope 3 emissions (categories 1-7)
- At our Cygnus Technologies facility in Leland, solar panels were installed in 2023 and are expected to offset the site’s energy use in 2024 and beyond
- We focused on waste initiatives, with many of our sites using biodegradable plastic bags for shipping and other processes
- We offer 292 hours of training in 14 environmental topics through our Learning Mangement system
Document Library
Reporting
Environmental documents
Social documents